Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care

Diabetes Mellitus, Type 2 Clinical Trial

— RELIANCE  

Official title:

A Randomised, Multicentre, Open-Label, Parallel-Group, 24-Week Phase IV Study Comparing the Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care: General Practitioner Initiation of Insulin Glargine Versus the Usual Standard of Care

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00950534
• Other study ID #: LANTU_L_04264
• Status: Terminated
• Phase: Phase 4
• First received: July 30, 2009
• Last updated: November 9, 2011
• Start date: July 2009
• Est. completion date: August 2010

Study information

• Verified date: November 2011
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The primary objective is to demonstrate the improvement in glycosylated haemoglobin (HbA1c) levels after general practitioner (GP) initiation and management of type 2 diabetes mellitus (T2DM) with insulin glargine compared with their usual clinical practice.

The secondary objective is to demonstrate the importance of GP initiation of insulin glargine for the treatment of T2DM.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria:

• Diagnosed with type 2 Diabetes Mellitus (T2DM)

• HbA1c > or = 7.5%, or HbA1c < or = 10%

• Continuous oral antidiabetic (OAD) treatment for more or equal than three months before randomisation with stable daily doses of one or more OADs (if on two or more OADs, one must be less or equal than half maximum tolerated dose)

• Willing and able to perform blood glucose monitoring using a blood glucose meter

• Willing and able to keep a daily patient diary

• Willing and able to provide written informed consent before enrolment in the study

Exclusion criteria:

• Type 1 diabetes mellitus

• Body mass index (BMI) > 45 kg/m²

• Works night shifts

• History of ketoacidosis or hyperosmolar hyperglycaemic state

• History of stroke, myocardial infarction, angina pectoris, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the previous 12 months

• History of congestive heart failure

• Hypoglycaemia unawareness

• Have had more than one episode of hypoglycaemia (per protocol definition) within 24 weeks before screening

• Impaired renal function defined as, but not limited to, serum creatinine > or = 1.5 mg/dL (133 µmol/L) males or > or = 1.4 mg/dL (124 µmol/L) females

• Active liver disease (alanine transaminase (ALT) greater than two times the upper limit of the reference range, as defined by the local laboratory)

• Have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol

• Had a blood transfusion or severe blood loss within the 3 months before screening, or have known haemoglobinopathy, haemolytic anaemia or sickle cell anaemia

• Current or previous use of insulin

• Known hypersensitivity / intolerance to insulin glargine or any of its excipients

• Have taken exenatide in the six weeks before screening or for a total of 30 days or more in the 24 weeks before screening

• Currently receiving treatment with non-selective -blockers

• Currently receiving chronic (longer than two weeks) systemic glucocorticoid therapy (excluding topical or inhaled preparations) or have received such therapy within the four weeks preceding the screening visit

• Currently undergoing therapy or planned radiological examinations requiring the administration of contrasting agents for malignancy (other than non-metastatic / early stage basal cell or squamous cell carcinoma).

• Currently participating in another investigational study or recent study participation ending < 30 days before screening

• Female patients who are pregnant or breastfeeding

• Female patients of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be willing to agree to use a medically accepted contraceptive regimen for the duration of the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• INSULIN GLARGINE (HOE901)
The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
• Oral Anti Diabetics (OAD)
Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L

Locations

Country	Name	City	State
Australia	Sanofi-Aventis Administrative Office	Macquarie Park

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of patients achieving glycosylated haemoglobin (HbA1c) levels < or = 7.0%		From week 0 to week 24	No
Secondary	Time required to reach the target HbA1c level of < or = 7%		From week 0 to week 24	No
Secondary	The percentage of patients achieving two consecutive on treatment HbA1c measurements of < or = 7.0%		From week 0 to week 24	No
Secondary	Decrease in mean HbA1c level		At week 24	No
Secondary	Decrease in mean Fasting Plasma Glucose (FPG)		At week 24	No
Secondary	Mean change in body weight		At week 24	No